```html

Zollinger‑Ellison Duodenal Ulcer

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) arise, most commonly in the duodenum or pancreas. The excess gastrin stimulates the stomach lining to release large amounts of gastric acid, leading to recurrent duodenal ulcers that are often resistant to standard ulcer therapy.

Although the syndrome itself is uncommon—affecting an estimated 1–3 per million people worldwide—duodenal ulcers caused by ZES represent a small fraction of all peptic ulcer disease cases (less than 5%). The condition can occur at any age but most patients are diagnosed between 30 and 60 years old. Both men and women are affected, with a slight male predominance (approximately 55 % male).

Zollinger‑Ellison duodenal ulcers are distinct from the more typical “stress” or “H. pylori‑related” ulcers because they tend to be multiple, located further downstream in the duodenum, and often produce severe, persistent symptoms despite acid‑suppressive therapy.

Symptoms

Symptoms arise from the combination of high gastric acid output and ulcer formation. They may be intermittent at first and become more constant as the disease progresses.

Common gastrointestinal symptoms

• Epigastric or upper‑abdominal pain – burning, gnawing, or cramping; often worsened by meals but may improve after eating in some patients.
• Heartburn/reflux – due to acid spilling into the esophagus.
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes, leading to malabsorption.
• Nausea and vomiting – may contain bile if obstruction occurs.
• Weight loss – from malabsorption and chronic pain.
• Upper‑GI bleeding – tarry (melena) or bright red stools when ulcers erode into vessels.

Systemic or “extra‑digestive” symptoms

• Fatigue or anemia (from chronic blood loss).
• Facial flushing or itching (rare, due to hormone secretion by the tumor).
• Abdominal distension or palpable mass (large gastrinomas can become palpable).

Causes and Risk Factors

Primary cause – Gastrinomas

Zollinger‑Ellison syndrome is caused by neuroendocrine tumors (NETs) that secrete gastrin. Over 90 % of gastrinomas are malignant, and about 25 % are part of the hereditary condition Multiple Endocrine Neoplasia type 1 (MEN‑1).

Risk factors

• MEN‑1 syndrome – a genetic disorder involving parathyroid, pituitary, and pancreatic NETs. Roughly 20–30 % of ZES patients have MEN‑1.
• Family history of gastrinomas or MEN‑1.
• Age – most tumors are diagnosed between 30–60 years.
• Gender – slight male predominance.
• Smoking – associated with higher risk of neuroendocrine tumor development.

Diagnosis

Because ZES ulcers are refractory to routine therapy, clinicians maintain a high index of suspicion when ulcers recur despite proton‑pump inhibitor (PPI) use, or when ulcers appear beyond the proximal duodenum.

Initial evaluation

1. Detailed history & physical exam – focus on ulcer pattern, diarrhea, weight loss, and family history of MEN‑1.
2. Laboratory tests
   • Fasting serum gastrin level – > 1000 pg/mL is highly suggestive; levels > 200 pg/mL with gastric pH < 2 are diagnostic.
   • Serum gastric pH – measured by a nasogastric aspirate; low pH confirms hyperacidity.
   • Chromogranin A – a tumor marker for neuroendocrine tumors, often elevated.

Imaging studies

• Endoscopic Ultrasound (EUS) – high‑resolution detection of small duodenal or pancreatic gastrinomas.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – best for locating metastatic disease.
• CT or MRI of the abdomen – assesses tumor size, local invasion, and liver metastases.
• Selective arterial secretin stimulation test – secretin paradoxically raises gastrin in ZES; used when fasting gastrin is equivocal.

Endoscopic assessment

Upper endoscopy (EGD) visualizes the ulcer(s) and can obtain biopsies to rule out malignancy from H. pylori or NSAID‑related ulcers.

Treatment Options

Management aims to control acid hypersecretion, remove or control the tumor, and address complications.

Acid‑suppression therapy (first line)

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 80 mg daily or esomeprazole 40 mg daily, titrated to symptom control. PPIs are more effective than H2‑blockers in ZES.
• Potassium‑competitive acid blockers (P‑CABs) such as vonoprazan (available in some countries) offer rapid, profound acid suppression and are an emerging option.

Acid control often requires lifelong high‑dose therapy, especially when metastatic disease is present.

Surgical management of gastrinomas

1. Resection of localized tumors – enucleation or pancreaticoduodenectomy for pancreatic gastrinomas; duodenal lesions may be removed endoscopically or surgically.
2. Debulking surgery – for metastatic disease, reduces tumor burden and may lower gastrin levels.
3. Curative surgery is feasible in ~30 % of sporadic ZES patients when the tumor is confined to the duodenum or pancreas.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and can shrink neuroendocrine tumors.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive metastatic NETs.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive tumors; shown to improve progression‑free survival.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and other ulcer‑promoting medications.
• Limit caffeine, alcohol, and very spicy foods that may aggravate symptoms.
• Maintain adequate nutrition; supplement fat‑soluble vitamins (A, D, E, K) if malabsorption is present.
• Vaccinate against hepatitis B and C if liver metastases are treated with chemo‑embolization.

Living with Zollinger‑Ellison Duodenal Ulcer

Medication adherence

Take PPIs exactly as prescribed—usually once or twice daily on an empty stomach. Missing doses can cause “rebound hyperacidity,” leading to severe pain.

Monitoring

• Regular follow‑up labs: fasting gastrin, chromogranin A, and liver function tests every 3–6 months.
• Imaging (CT/MRI or Ga‑68 DOTATATE PET) every 6–12 months to track tumor growth.
• Endoscopy every 1–2 years to assess ulcer healing and screen for gastric dysplasia.

Nutrition tips

• Eat small, frequent meals to avoid overwhelming acid production.
• Include a balanced mix of protein, complex carbohydrates, and healthy fats; consider medium‑chain triglyceride (MCT) oil if fat malabsorption is severe.
• Stay hydrated; chronic diarrhea can cause electrolyte imbalance (especially potassium and magnesium).

Psychosocial support

Living with a chronic rare disease can be stressful. Connect with patient advocacy groups such as the North American Neuroendocrine Tumor Society (NANETS) or local support circles. Consider counseling if anxiety or depression develops.

Prevention

Because ZES is driven by tumor genetics, primary prevention is limited. However, the following measures can reduce ulcer‑related complications:

• Do not use NSAIDs or COX‑2 inhibitors unless prescribed; use acetaminophen for pain when possible.
• Limit alcohol consumption to ≤ 1 drink per day for women and ≤ 2 drinks per day for men.
• Quit smoking – it increases gastrin secretion and may accelerate tumor growth.
• Promptly treat H. pylori infection if present; eradication does not cure ZES but reduces additive ulcer risk.

Complications

If untreated or inadequately controlled, Zollinger‑Ellison duodenal ulcers can lead to serious outcomes:

• Bleeding – leading to anemia, hemodynamic instability, or need for endoscopic/surgical hemostasis.
• Perforation – free air in the abdomen causing peritonitis; surgical emergency.
• Obstruction – ulcer scarring can narrow the duodenum or pylorus.
• Malabsorption & Nutritional deficiencies – chronic diarrhea leads to weight loss, vitamin deficiencies, and osteoporosis.
• Metastatic disease – liver, lymph nodes, or bone metastases occur in up to 50 % of patients at diagnosis.
• Gastric carcinoid tumors – hypergastrinemia can stimulate enterochromaffin‑like (ECL) cells, rarely progressing to carcinoid.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic, Cleveland Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Cancer Society, European Neuroendocrine Tumor Society (ENETS) guidelines, Journal of Clinical Oncology 2023, WHO Neuroendocrine Tumor Fact Sheet 2022.

```